🚨 “Do no harm” alert. At #AACR26, #ChaeLab presented the results from the pooled analyses (lung, bladder, and head & neck cancer trials) that revealed the "early progression gap" when using first-line immunotherapy-only vs. chemotherapy! 🔬📊

While immunotherapy eventually offers durable long-term benefits ⏳✨, patients face a higher risk of early progression 📉⚠️. The Hazard Ratios (HR) of PFS tell the story:
• Bladder Cancer 🚽: 4.08 (3-mo) / 2.87 (6-mo)
• Head & Neck Cancer 🗣️: 3.77 (3-mo) / 2.20 (6-mo)
• NSCLC 🫁: 2.03 (3-mo) / 1.36 (6-mo)
This early disadvantage may result from delayed immune activation 🧬 or the phenomenon of hyperprogression—an aggressive, rapid acceleration of disease 🚀📉.

These findings highlight the absolute need for vigilant early assessment 🔍🩺. Clinicians may want to consider combination or sequential treatment strategies to bridge this high-risk window while protecting the long-term benefits of immunotherapy 💊🤝🛡️.
@OncoAlert @NUFeinbergMed @NorthwesternMed @LurieCancer @oncodaily